Steward Partners Investment Advisory LLC Raises Position in ARS Pharmaceuticals, Inc. (NASDAQ:SPRY)

Steward Partners Investment Advisory LLC raised its holdings in ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) by 47.2% in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 38,050 shares of the company’s stock after buying an additional 12,200 shares during the period. Steward Partners Investment Advisory LLC’s holdings in ARS Pharmaceuticals were worth $401,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in the business. Compass Capital Corp MA ADV acquired a new stake in shares of ARS Pharmaceuticals in the 4th quarter valued at $106,000. Quarry LP acquired a new stake in shares of ARS Pharmaceuticals in the 3rd quarter valued at $174,000. SBI Securities Co. Ltd. acquired a new stake in shares of ARS Pharmaceuticals in the 4th quarter valued at $175,000. Stifel Financial Corp acquired a new stake in shares of ARS Pharmaceuticals in the 3rd quarter valued at $199,000. Finally, China Universal Asset Management Co. Ltd. raised its holdings in shares of ARS Pharmaceuticals by 10.5% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 20,607 shares of the company’s stock valued at $217,000 after purchasing an additional 1,962 shares in the last quarter. Hedge funds and other institutional investors own 68.16% of the company’s stock.

Analyst Ratings Changes

Several brokerages recently commented on SPRY. Raymond James lifted their price target on shares of ARS Pharmaceuticals from $26.00 to $28.00 and gave the stock a “strong-buy” rating in a research note on Tuesday, January 14th. William Blair reiterated an “outperform” rating on shares of ARS Pharmaceuticals in a research note on Monday, March 3rd. Leerink Partners lifted their price target on shares of ARS Pharmaceuticals from $26.00 to $27.00 and gave the stock an “outperform” rating in a research note on Monday, January 13th. Scotiabank began coverage on shares of ARS Pharmaceuticals in a research note on Friday, March 7th. They set a “sector outperform” rating and a $30.00 price target on the stock. Finally, Oppenheimer began coverage on shares of ARS Pharmaceuticals in a research note on Monday, February 10th. They set an “outperform” rating and a $40.00 price target on the stock. Five investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat.com, ARS Pharmaceuticals has a consensus rating of “Buy” and a consensus price target of $31.00.

ARS Pharmaceuticals Stock Performance

Shares of ARS Pharmaceuticals stock opened at $11.95 on Friday. ARS Pharmaceuticals, Inc. has a 1 year low of $7.55 and a 1 year high of $18.51. The company has a market capitalization of $1.16 billion, a P/E ratio of -23.43 and a beta of 1.04. The company’s fifty day moving average is $11.93 and its two-hundred day moving average is $13.09.

Insiders Place Their Bets

In other news, insider Sarina Tanimoto sold 100,000 shares of ARS Pharmaceuticals stock in a transaction dated Tuesday, December 17th. The shares were sold at an average price of $11.67, for a total value of $1,167,000.00. Following the sale, the insider now owns 1,098,499 shares of the company’s stock, valued at $12,819,483.33. The trade was a 8.34 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Laura Shawver sold 50,000 shares of ARS Pharmaceuticals stock in a transaction dated Monday, January 6th. The shares were sold at an average price of $11.10, for a total transaction of $555,000.00. Following the completion of the sale, the director now directly owns 210,346 shares in the company, valued at approximately $2,334,840.60. The trade was a 19.21 % decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders have sold 249,600 shares of company stock valued at $2,893,516. Insiders own 40.10% of the company’s stock.

ARS Pharmaceuticals Company Profile

ARS Pharmaceuticals, Inc, a biopharmaceutical company, develops treatments for severe allergic reactions. The company is developing neffy, a needle-free and low-dose intranasal epinephrine nasal spray for the emergency treatment of Type I allergic reactions, including anaphylaxis. It serves healthcare professionals, patients, and caregivers.